Metraipolis › archive › dc_2fb10dbbd469

N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses — Europe PMC PMID:39348391

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39348391
DOI
10.1371/journal.ppat.1012574
License (as archived)
CC0-1.0
Archived
2026-10-06T15:19:14.971Z
SHA-256 of the archived text
f0ae0296c456b4d94dc2f2f45472a56a79697cf19a29dc48f95a56c1c2837193
Stable URL of this page
https://metraipolis.com/documento/dc_2fb10dbbd469

How to cite

N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses — Europe PMC PMID:39348391 — Europe PMC (en), https://europepmc.org/article/MED/39348391 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2fb10dbbd469 (Metraipolis archive dc_2fb10dbbd469, sha256 f0ae0296c456b4d94dc2f2f45472a56a79697cf19a29dc48f95a56c1c2837193)
BibTeX
@misc{dc2fb10dbbd469,
  title = {N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses — Europe PMC PMID:39348391},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39348391},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2fb10dbbd469; sha256 f0ae0296c456b4d94dc2f2f45472a56a79697cf19a29dc48f95a56c1c2837193},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/39348391. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

A diverse group of RNA viruses have the ability to gain access to the central nervous system (CNS) and cause severe neurological disease. Current treatment for people with this type of infection is generally limited to supportive care. To address the need for reliable antivirals, we utilized a strategy of lethal mutagenesis to limit virus replication. We evaluated ribavirin (RBV), favipiravir (FAV) and N4-hydroxycytidine (NHC) against La Crosse virus (LACV), which is one of the most common causes of pediatric arboviral encephalitis cases in North America and serves as a model for viral CNS invasion during acute infection. NHC was approximately 3 to 170 times more potent than RBV or FAV in neuronal cells. Oral administration of molnupiravir (MOV), the prodrug of NHC, decreased neurological disease development (assessed as limb paralysis, ataxia and weakness, repeated seizures, or death) by 31% (4 mice survived out of 13) when treatment was started on the day of infection. MOV also reduced disease by 23% when virus was administered intranasally (IN). NHC and MOV produced less fit viruses by incorporating predominantly G to A or C to U mutations. Furthermore, NHC also inhibited virus production of two other orthobunyaviruses, Jamestown Canyon virus and Cache Valley virus. Collectively, these studies indicate that NHC/MOV has therapeutic potential to inhibit viral replication and subsequent neurological disease caused by orthobunyaviruses and potentially as a generalizable strategy for treating acute viral encephalitis.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2024 (prima pubblicazione 2024-09-30).
Identificativi: PMID 39348391 · PMCID PMC11493283 · DOI 10.1371/journal.ppat.1012574.
Descrittori MeSH principali: La Crosse virus; Cytidine; Antiviral Agents; Virus Replication.
Pagina: https://europepmc.org/article/MED/39348391 — https://doi.org/10.1371/journal.ppat.1012574. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T15:11:56.378Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.